Molecular Testing for Bethesda III Thyroid Nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution
Authors' conclusion
The use of MT increased across the institution over the study period, with the largest increase seen after a dedicated pass for MT was routinely collected. This increased availability of MT may have led to an unintended increase in the rates of BIII lesions, MT utilization, and surgery for benign nodules.
Study context
- Population
- All thyroid fine-needle aspirations (FNAs) analysed at a tertiary medical center with community and academic sites, 2017–2021
- Participants
- 8,960 FNAs
- Exposure
- Pre-MT vs post-MT periods
- Outcome
- BIII call rate and MT utilisation
Methodological detailssingle institution
- Single institution
Main finding
As reported in the abstract
- Significant increase in BIII rate between pre- and post-MT periods
- p < 0.001
- Significant increase in molecular testing (MT) utilisation between pre- and post-MT periods
- p < 0.001
Observational data: associations, not effects.
Further findings
PPV of MT · PPV decreased
(CI 9.5–52.5%) · P = 0.008
- Malignancy yield on final pathology — No significant change in malignancy yield · no significant change
- 57.1% vs. 50.0% · P = 0.347
Original publication
Molecular Testing for Bethesda III Thyroid Nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution. Thyroid. Published 4 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →